JG
KPTI icon

Jefferies Group’s Karyopharm Therapeutics KPTI Stock Holding History

Jefferies Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$555K Buy
+6,780
New +$506K ﹤0.01% 1003
2022
Q2 		– Sell
-7
Closed -$737 – 1722
2022
Q1 		$737 Buy
+7
New +$872 ﹤0.01% 1492
2019
Q2 		– Sell
-520
Closed -$46K – 2711
2019
Q1 		$46K Buy
+520
New +$57.6K ﹤0.01% 2204

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Jefferies Group's KPTI Position: Q3 2022 in Review

Jefferies Group opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2022: 6,780 shares worth $555K. The stake represents ﹤0.01% of the portfolio and ranks #1003 among its holdings. This is a return to the name: Jefferies Group previously reported a position in KPTI as recently as Q1 2022.

Jefferies Group first reported a position in KPTI in Q1 2019 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Jefferies Group held 6,780 shares of Karyopharm Therapeutics worth $555K as of Q3 2022.
  • Karyopharm Therapeutics was a new Jefferies Group position in Q3 2022.
  • Karyopharm Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1003 holding.
  • Jefferies Group first reported a position in Karyopharm Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.